留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版)

中华医学会器官移植学分会

中华医学会器官移植学分会. 器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版)[J]. 器官移植, 2019, 10(2): 149-157. doi: 10.3969/j.issn.1674-7445.2019.02.006
引用本文: 中华医学会器官移植学分会. 器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版)[J]. 器官移植, 2019, 10(2): 149-157. doi: 10.3969/j.issn.1674-7445.2019.02.006

器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版)

doi: 10.3969/j.issn.1674-7445.2019.02.006
基金项目: 

国家自然科学基金 81570680

国家自然科学基金 81571555

详细信息
    通讯作者:

    张永清,Email:13811869793@163.com

  • 中图分类号: R617, R733

  • 摘要: 为了进一步规范中国实体器官移植(SOT)受者EB病毒(EBV)感染和移植后淋巴组织增生性疾病(PTLD)的诊断和治疗,中华医学会器官移植学分会组织器官移植专家、感染病学专家、血液内科专家,在《器官移植受者EBV感染和PTLD临床诊疗指南(2016版)》的基础上,从概述和流行病学特点、临床表现、诊断、预防、治疗、预后、存在的问题及展望等方面,制订本规范,以帮助器官移植工作者规范和优化EBV感染及相关疾病PTLD的诊断和治疗。

     

  • 图  1  PTLD不同组织学分类的组织病理学检查(Giemsa)

    A图为PTLD早期病变,生发中心内可见不同程度淋巴细胞浸润(主要为小淋巴细胞、浆细胞等);B图为多形性PTLD,可见免疫母细胞及中等大小的淋巴细胞异常增生(增生淋巴细胞中可见形态不规则核仁);C图为单形性B细胞PTLD,可见大量的形成单一的大B细胞异常增生,多数细胞可见圆形核仁;D图为经典霍奇金淋巴瘤PTLD,在增生小淋巴细胞的背景中可见散在分布的单核和多核霍奇金淋巴瘤细胞(如箭头所示)

    Figure  1.  Histopathological examination of different histological classifications in PTLD

    表  1  2008年WHO的PTLD组织学分类

    Table  1.   PTLD histological classification of WHO in 2008

    类型 组织学分类
    早期病变 浆细胞增生
    传染性单核细胞增多症样PTLD
    多形性PTLD
    单形性PTLD(依据类似的淋巴瘤分类)
    B细胞淋巴瘤 弥漫性大B细胞淋巴瘤Burkitt淋巴瘤
    浆细胞骨髓瘤
    浆细胞瘤样
    其他
    T细胞淋巴瘤 外周T细胞淋巴瘤,非特指型
    肝脾T细胞淋巴瘤
    其他
    经典霍奇金淋巴瘤型PTLD
    下载: 导出CSV

    表  2  2016年WHO的PTLD组织学分类

    Table  2.   PTLD histological classification of WHO in 2016

    类型 组织学分类
    早期病变 浆细胞增生性PTLD
    传染性单核细胞增多症样PTLD
    旺炽性滤泡增生性PTLD
    多形性PTLD
    单形性PTLD(依据类似的淋巴瘤分类)
    B细胞淋巴瘤 弥漫性大B细胞淋巴瘤
    Burkitt淋巴瘤
    浆细胞骨髓瘤
    浆细胞瘤样
    其他
    T细胞淋巴瘤 外周T细胞淋巴瘤,非特指型肝脾T细胞淋巴瘤
    其他
    经典霍奇金淋巴瘤型PTLD
    下载: 导出CSV
  • [1] ISON MG, GROSSI P, AST Infectious Diseases Community of Practice. Donor-derived infections in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4):22-30. DOI: 10.1111/ajt.12095.
    [2] GRIM SA, CLARK NM. Management of infectious complications in solid-organ transplant recipients[J]. Clin Pharmacol Ther, 2011, 90(2):333-342. DOI: 10.1038/clpt.2011.90.
    [3] ALLEN UD, PREIKSAITIS JK, AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4):107-120. DOI: 10.1111/ajt.12104.
    [4] SAN-JUAN R, MANUEL O, HIRSCH HH, et al. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. results of the ESGICH questionnaire-based cross-sectional Survey[J]. Clin Microbiol Infect, 2015, 21(6):604.e1-604.e9. DOI: 10.1016/j.cmi.2015.02.002.
    [5] SAN-JUAN R, COMOLI P, CAILLARD S, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients[J]. Clin Microbiol Infect, 2014, 20(Suppl 7):109-118. DOI: 10.1111/1469-0691.12534.
    [6] LOWENBERG B. How I treat[M]. 3 ed. Washington: Blood Journal Press, 2018: 296-305.
    [7] COHEN JI. Epstein-Barr virus infection[J]. N Engl J Med, 2000, 343(7):481-492. doi: 10.1056/NEJM200008173430707
    [8] SWERDOW SH, WEBBER SA, CHADBUMA, et al. WHO classification of haematopoietic and lymphoid tissues[M]. Lyon: IARC Press, 2008: 343-349.
    [9] ALLEN U, HÉBERT D, MOORE D, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience[J]. Pediatr Transplant, 2001, 5(3):198-203. doi: 10.1034/j.1399-3046.2001.00059.x
    [10] HOSHIDA Y, LI T, DONG Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan[J]. Int J Cancer, 2001, 91(6):869-875. doi: 10.1002/(ISSN)1097-0215
    [11] CHAN TS, HWANG YY, GILL H, et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment[J]. Clin Transplant, 2012, 26(5):679-683. DOI: 10.1111/j.1399-0012.2011.01593.x.
    [12] GREEN M, MICHAELS MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder[J]. Am J Transplant, 2013, 13(Suppl 3):41-54. DOI: 10.1111/ajt.12004.
    [13] DIERICKX D, HABERMANN TM. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018, 378(6):549-562. DOI: 10.1056/NEJMra1702693.
    [14] NALESNIK M, JAFFE R, REYES J, et al. Posttransplant lymphoproliferative disorders in small bowel allograft recipients[J]. Transplant Proc, 2000, 32(6):1213. doi: 10.1016/S0041-1345(00)01191-X
    [15] TSAO L, HSI ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders[J]. Arch Pathol Lab Med, 2007, 131(8):1209-1218. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Open J-Gate000002328336
    [16] EBV Work Group, Cincinnati Children' s Hospital Medical Center. Evidence-based clinical care guideline for management of EBV-associated post-transplant lymphoproliferative disease in solid organ transplant[EB/OL].[2019-12-26]. http://www.cincinnatichildrens.org/svc/alpha/h/healthpolicy/guidelines.htm.
    [17] CASTILLO JJ, BIBAS M, MIRANDA RN. The biology and treatment of plasmablastic lymphoma[J]. Blood, 2015, 125(15):2323-2330. DOI: 10.1182/blood-2014-10-567479.
    [18] EVENS AM, CHOQUET S, KROLL-DESROSIERS AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era[J]. Am J Transplant, 2013, 13(6):1512-1522. DOI: 10.1111/ajt.12211.
    [19] 苗芸, 于立新, 邓文锋, 等.国内报道移植后淋巴增殖性疾病的总结分析[J/CD].实用器官移植电子杂志, 2013, 1(5): 276-281.DOI: 10.3969/j.issn.2095-5332.2013.05.002.

    MIAO Y, YU LX, DENG WF, et al. Post-transplant lymphoproliferative disorders: a summary analysis of reported cases in China[J/CD]. Pract J Organ Transplant (Electr Vers), 2013, 1(5): 276-281.DOI: 10.3969/j.issn.2095-5332.2013.05.002.
    [20] BUELL JF, GROSS TG, WOODLE ES. Malignancy after transplantation[J]. Transplantation, 2005, 80(2 Suppl):S254-S264. http://d.old.wanfangdata.com.cn/Periodical/zhxyx201710002
    [21] SWERDLOW SH. Pathology[M]//DHARNIDHARKA VR, GREEN M, WEBBER SA. Post-transplant lymphoproliferative disorders. Berlin and Heidelberg: Springer-Verlag, 2010: 89-104.
    [22] DIERICKX D, TOUSSEYN T, GHEYSENS O. How I treat posttransplant lymphoproliferative disorders[J]. Blood, 2015, 126(20):2274-2283. DOI: 10.1182/blood-2015-05-615872.
    [23] WADOWSKY RM, LAUS S, GREEN M, et al. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR[J]. J Clin Microbiol, 2003, 41(11):5245-5249. doi: 10.1128/JCM.41.11.5245-5249.2003
    [24] PARKER A, BOWLES K, BRADLEY JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines[J]. Br J Haematol, 2010, 149(5):675-692. DOI: 10.1111/j.1365-2141.2010.08161.x.
    [25] PARKER A, BOWLES K, BRADLEY JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS guidelines[J]. Br J Haematol, 2010, 149(5):693-705. DOI: 10.1111/j.1365-2141.2010.08160.x.
    [26] SWERDLOW SH, CAMPO E, PILERI SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375-2390.DOI: 10.1182/blood-2016-01-643569.
    [27] VAKIANI E, NANDULA SV, SUBRAMANIYAM S, et al. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion[J]. Hum Pathol, 2007, 38(2):315-325. doi: 10.1016/j.humpath.2006.08.014
    [28] KRISHNAMURTHY S, HASSAN A, FRATER JL, et al. Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease[J]. Int J Surg Pathol, 2010, 18(4):278-285. DOI: 10.1177/1066896909338597.
    [29] ZIMMERMANN H, OSCHLIES I, FINK S, et al. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry[J]. Transplantation, 2012, 93(5):543-550. DOI: 10.1097/TP.0b013e318242162d.
    [30] MORSCIO J, DIERICKX D, NIJS J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and Meta-analysis of 277 reported cases[J]. Am J Surg Pathol, 2014, 38(7):875-886. DOI: 10.1097/PAS.0000000000000234.
    [31] TAOKA K, NANNYA Y, YAMAMOTO G, et al. Progressive transition of Epstein-Barr virus associated lymphoproliferative disease subtypes with the development of lung cancer[J]. Am J Hematol, 2009, 84(9):600-603. DOI: 10.1002/ajh.21479.
    [32] TAKEHANA CS, TWIST CJ, MOSCI C, et al. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder[J]. Nucl Med Commun, 2014, 35(3):276-281. DOI: 10.1097/MNM.0000000000000050.
    [33] PITMAN SD, HUANG Q, ZUPPAN CW, et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically[J]. Am J Surg Pathol, 2006, 30(4):470-476. doi: 10.1097/00000478-200604000-00007
    [34] HART M, THAKRAL B, YOHE S, et al. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder[J]. Am J Surg Pathol, 2014, 38(11):1522-1529. DOI: 10.1097/PAS.0000000000000282.
    [35] LUSKIN MR, HEIL DS, TAN KS, et al. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder[J]. Am J Transplant, 2015, 15(10):2665-2673. DOI: 10.1111/ajt.13324.
    [36] CRAIG FE, JOHNSON LR, HARVEY SA, et al. Gene expression profiling of Epstein-Barr virus-positive and-negative monomorphic B-cell posttransplant lymphoproliferative disorders[J]. Diagn Mol Pathol, 2007, 16(3):158-168. doi: 10.1097/PDM.0b013e31804f54a9
    [37] STUHLMANN-LAEISZ C, OSCHLIES I, KLAPPER W.Detection of EBV in reactive and neoplastic lymphoproliferations in adults-when and how?[J]. J Hematop, 2014, 7(4):165-170. doi: 10.1007/s12308-014-0209-0
    [38] KAPELUSHNIK J, ARIAD S, BENHARROCH D, et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi' s sarcoma[J]. Br J Haematol, 2001, 113(2):425-428. doi: 10.1046/j.1365-2141.2001.02740.x
    [39] CHEN W, HUANG Q, ZUPPAN CW, et al. Complete absence of KSHV/HHV-8 in posttransplant lymphoproliferative disorders: an immunohistochemical and molecular study of 52 cases[J]. Am J Clin Pathol, 2009, 131(5):632-639. DOI: 10.1309/AJCP2T4IIIZKBHMI.
    [40] Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 3):S1-S155. DOI: 10.1111/j.1600-6143.2009.02834.x.
    [41] TSAI DE, HARDY CL, TOMASZEWSKI JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients[J]. Transplantation, 2001, 71(8):1076-1088. doi: 10.1097/00007890-200104270-00012
    [42] GONZÁLEZ-BARCA E, DOMINGO-DOMENECH E, CAPOTE FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease[J]. Haematologica, 2007, 92(11):1489-1494. doi: 10.3324/haematol.11360
    [43] CHOQUET S, LEBLOND V, HERBRECHT R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study[J]. Blood, 2006, 107(8):3053-3057. doi: 10.1182/blood-2005-01-0377
    [44] OERTEL SH, VERSCHUUREN E, REINKE P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)[J]. Am J Transplant, 2005, 5(12):2901-2906. doi: 10.1111/j.1600-6143.2005.01098.x
    [45] KINCH A, BAECKLUND E, BACKLIN C, et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival[J]. Acta Oncol, 2014, 53(5):669-679. DOI: 10.3109/0284186X.2013.844853.
    [46] EVENS AM, DAVID KA, HELENOWSKI I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era[J]. J Clin Oncol, 2010, 28(6):1038-1046. DOI: 10.1200/JCO.2009.25.4961.
    [47] TRAPPE R, OERTEL S, LEBLOND V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial[J]. Lancet Oncol, 2012, 13(2):196-206. DOI: 10.1016/S1470-2045(11)70300-X.
    [48] TRAPPE RU, CHOQUET S, DIERICKX D, et al. International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial[J]. Am J Transplant, 2015, 15(4):1091-1100. DOI: 10.1111/ajt.13086.
  • 加载中
图(1) / 表(2)
计量
  • 文章访问数:  346
  • HTML全文浏览量:  233
  • PDF下载量:  137
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-12-28
  • 网络出版日期:  2021-04-27
  • 刊出日期:  2019-03-15

目录

    /

    返回文章
    返回